What to Know About Treatment Options Before and After Surgery for Early-Stage Non-Small Cell Lung Cancer

For folks identified with early-stage non-small cell lung cancer (NSCLC) who shall be receiving surgical procedure, the physician could advocate extra remedies given both earlier than or after the process. Early-stage lung most cancers is most cancers that’s stage I through stage III. These extra remedies could embrace chemotherapy, immunotherapy, focused remedy, or a mix of therapies. When therapy is given earlier than surgical procedure, it’s known as “neoadjuvant remedy.” When therapy is given after surgical procedure, it’s known as “adjuvant remedy.”

On this podcast, Charu Aggarwal, MD, MPH, and Ryan Gentzler, MD, talk about what folks with early-stage NSCLC ought to find out about their neoadjuvant and adjuvant therapy choices, together with what to contemplate when selecting therapy and inquiries to ask the well being care staff.

• What are neoadjuvant remedy and adjuvant remedy? [02:13]

• Why ought to folks with early-stage NSCLC take into account neoadjuvant remedy? [05:21]

• What analysis has been accomplished on neoadjuvant remedies for folks with early-stage NSCLC? [09:03]

• What questions ought to folks with early-stage NSCLC ask their well being care staff when contemplating neoadjuvant remedy? [15:05]

• When do medical doctors usually advocate adjuvant therapy for folks with early-stage NSCLC? [21:08]

• Why is it vital to contemplate whether or not checks present sure mutations, akin to an EGFR mutation, when discussing adjuvant therapy choices? [22:28]

• What are among the accredited adjuvant therapy choices for folks with early-stage NSCLC? [24:29]

Dr. Aggarwal is the Leslye Heisler Affiliate Professor of Drugs within the Hematology-Oncology Division on the College of Pennsylvania’s Perelman Faculty of Drugs. She can also be the 2023 Cancer.Net Associate Editor for Lung Cancer. Dr. Gentzler is a thoracic medical oncologist and Affiliate Professor of Drugs within the Division of Hematology/Oncology on the College of Virginia (UVA) Complete Most cancers Heart. He’s additionally the 2023 Cancer.Net Specialty Editor for Thymoma.

Disclosure data for Dr. Aggarwal and Dr. Gentzler might be discovered of their particular person biographies linked to within the paragraph above.

Was this podcast helpful? Please subscribe, price, and assessment Most cancers.Web Podcasts wherever you hearken to podcasts. This prerecorded podcast might be listened to on-line or downloaded to your laptop. A transcript can also be out there. For extra data, go to the Cancer.Net podcast page.

Most cancers.Web podcasts are edited for size and content material.